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Abstract 
 
Background: Combat-related posttraumatic stress disorder (PTSD) is severe form of PTSD, 
frequently associated with psychotic symptoms. Platelet serotonin (5-hydroxytryptamine, 5-
HT) was used as a peripheral 5-HT marker to identify particular symptoms in PTSD.  
Methods: Platelet 5-HT was determined fluorimetrically in 67 war veterans with combat 
related PTSD, 36 combat exposed veterans who did not develop PTSD, 35 veterans with 
PTSD complicated with psychotic features. PTSD diagnosis of current and chronic PTSD, 
and clinical symptoms of PTSD and psychoses were assessed according to DSM-IV criteria, 
using the Clinician Administrated PTSD Scale, and Positive and Negative Syndrome Scale 
(PANSS). 
Results: Platelet 5-HT concentration was significantly higher in veterans with psychotic PTSD 
than in veterans with non-psychotic PTSD, veterans without PTSD, or in control subjects. 
Platelet 5-HT was significantly positively correlated with the positive symptoms in PANSS 
subscale, and with the symptoms of delusions within PANSS positive subscale.  
Limitations: The results were obtained on peripheral 5-HT marker, i.e. platelet 5-HT 
concentration. 
Conclusions: Since the delusions are the core psychotic symptoms occurring in our psychotic 
PTSD patients, the result of the increased platelet 5-HT concentration, associated with 
delusions, indicate that platelet 5-HT might be used as a trait marker of psychotic symptoms 
in PTSD, but not as a state marker for PTSD. 
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1. Introduction  
 
Posttraumatic stress disorder (PTSD) occurs after an extreme, life threatening traumatic 
event. Combat-related PTSD is a severe form of PTSD, sometimes associated with psychotic 
symptoms (Hamner, 1997; Hamner et al., 1999). The underlying neurobiological dysfunction 
of PTSD includes the abnormalities in different neurotransmitter and neuroendocrine systems 
(Morgan III et al., 2003). Serotonin (5-hydroxytryptamine, 5-HT) is implicated in the 
pathophysiology of PTSD, since 5-HT alterations might contribute to the cognitive 
disturbances in PTSD (van Praag, 2004) and aggression (Goveas et al., 2004), 5-HT drugs 
(sertraline) show clinical efficacy of in the treatment of PTSD (Brady et al., 2000), and 
administration of the 5-HT2 agonist meta-chlorophenylpiperazine provokes PTSD symptoms 
(Southwick et al., 1997).  
Blood platelets share similarities (receptors, transporter, uptake, storage and release of 5-
HT) with the central 5-HT synaptosomes (Camacho and Dimsdale, 2000; Stahl, 1985), and 
platelet 5-HT has been associated with depressive symptoms in PTSD (Muck-Seler et al., 
2003), and aggression (Goveas et al., 2004). Since biological markers are associated to single 
psychological dysfunction (Mueller-Oerlinghausen et al., 2004; van Praag, 2004), we 
hypothesized that platelet 5-HT concentration might be related with specific PTSD or 
psychotic symptoms in patients with combat related PTSD. The aim of the study was to 
evaluate the association between particular PTSD or psychotic symptoms, and platelet 5-HT 
concentration, in drug-free male war veterans with combat related PTSD, combat-exposed 
war veterans who did not develop PTSD, war veterans who had PTSD complicated with 
psychotic symptoms, and in healthy male control subjects. 
 
2. Materials and methods  
  
Participants were 39.4 ± 7.1 years old (range 24-56 years) male, drug-free war 
veterans (N=138) with chronic and current combat related PTSD, hospitalized at the 
Department of Psychiatry, University Hospital Dubrava, during 2001-2004 period. Diagnosis 
of chronic and current combat related PTSD was established using Structured Clinical 
Interview (SCID) based on DSM-IV criteria (APA, 1994). Groups were divided into 67 
veterans with PTSD, 35 veterans with psychotic PTSD, and 36 veterans who did not develop 
PTSD. PTSD and psychotic symptoms were assessed with Clinician Administrated PTSD 
Scale (CAPS) (Weathers et al., 2001), and Positive and Negative Syndrome Scale (PANSS) 
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(Kay et al., 1987). Only patients with total Hamilton Rating Scale for Depression (HAMD) 
scores ≤ 18 (Hamilton, 1960) were included. The onset of PTSD in psychotic PTSD patients 
preceded the onset of psychosis. Psychotic symptoms (hallucinations or delusions on the 
psychotic module of the SCID, or specific disturbance in form of thoughts by mental status 
examination) and exclusion/inclusion criteria were described in our previous papers (Pivac et 
al., 2004a; Kozaric-Kovacic et al., 2005). The procedure was fully explained and written 
informed consent was obtained from all patients. Human ethics committee of the University 
Hospital Dubrava approved this protocol.  
Control group consisted of 136 male drug-free healthy controls, mainly medical stuff, 
with no personal or family history of psychopathology, substance abuse or dependence, and no 
medical treatment. Veterans and healthy controls were sampled in the same period of the year.  
Blood (4 ml) was drawn from cubical vein at 8.00 a.m. in a plastic syringe with 1 ml of 
acid citrate dextrose (ACD) anticoagulant. Platelet 5-HT concentrations were determined by the 
spectrofluorimetric method, as described before (Pivac et al., 2004b). Platelet protein was 
determined by the method of Lowry et al. (1951). 
Statistical evaluation of the results, expressed as means ± SD, was done using one-way 
analysis of variance (ANOVA), followed by a Tukey’s multiple comparison test, and 
correlations were determined by a Pearson’s coefficient of correlation. The significance was 
accepted when p<0.05. 
 
3. Results  
 
 The demographic data are presented in Table 1. Platelet 5-HT concentration differed 
significantly (F(3,266)=3.387, p=0.019), with significantly (Tukey’s test) higher platelet 5-HT 
concentration in veterans with psychotic PTSD than in veterans with PTSD (p=0.019), 
without PTSD (p=0.040), or in control subjects (p=0.029). Platelet 5-HT concentration did not 
differ significantly (p>0.05) between control subjects, veterans with PTSD or veterans who 
did not develop PTSD (Fig. 1).  
Age of the subjects (Table 1) differed significantly (F(3,266)=10.839, p=0.000), and 
control subjects (33.04 ± 11.24 years) were significantly (Tukey’s test) younger than veterans 
with PTSD (p=0.000), without PTSD (p=0.037), or with psychotic PTSD (p=0.019).  
No significant correlation was found between platelet 5-HT concentration and age in 
control subjects (r=-0.013; p=0.909), veterans with PTSD (r=0.078; p=0.531), without PTSD 
(r=-0.023; p=0.896), or with psychotic PTSD (r=-0.222; p=0.208).  
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Since platelet 5-HT was significantly increased in 35 psychotic PTSD patients, to find 
out the association between platelet 5-HT concentration and psychotic symptoms, a 
correlation between platelet 5-HT and the corresponding total and subscale scores in PANSS 
and CAPS was evaluated in these patients (Table 2). Platelet 5-HT concentration was 
significantly correlated with the scores in PANSS positive subscale. Scores in other subscales 
in the PANSS or CAPS were not significantly related to platelet 5-HT concentration. To find 
out which symptoms were related with the increased platelet 5-HT concentration, platelet 5-
HT was correlated with each single item listed in PANSS positive subscale. Platelet 5-HT 
concentration was significantly correlated with the symptoms of delusions. Other symptoms 
were not significantly correlated with platelet 5-HT concentration (Table 2). 
 
4. Discussion 
 
Our results showed that platelet 5-HT concentration was increased in drug-free 
veterans with chronic and current combat related PTSD complicated with psychotic features, 
when compared to veterans with or without PTSD, or to control subjects. A positive 
correlation was found between platelet 5-HT and positive symptoms listed in PANSS 
subscale, and this correlation was due to the relationship between increased platelet 5-HT and 
delusions.  
The highest platelet 5-HT concentration was found in psychotic PTSD patients with 
delusions. This finding agrees with the association between platelet 5-HT content and 
aggression (Goveas et al., 2004), impulsivity and violence (Askenazy et al., 2000), psychotic 
symptoms of depression (Muck-Seler et al., 1996a; Pivac et al., 1997a), delusions in dementia 
(Meszaros et al., 1998), positive (Pivac et al., 1997b) or paranoid (Muck-Seler et al., 1991) 
symptoms of schizophrenia, supporting the hypothesis that platelet 5-HT concentration is 
related to trait markers (Askenazy et al., 2000; Peirson et al., 1999), such as psychotic 
symptoms in PTSD (present study). Our data suggest that platelet 5-HT may distinguish 
between PTSD subjects with and without psychotic symptoms. In line with previous data 
(Maguire et al., 1998; Mellman and Kumar, 1994; Muck-Seler et al., 2003; Pivac et al., 2002), 
our veterans with or without combat related PTSD had similar platelet 5-HT concentration as 
control subjects or combat exposed veterans who did not develop PTSD, indicating that 
platelet 5-HT is not associated with diagnosis of PTSD (van Praag, 2004). Platelet 5-HT 
concentration might be affected by sex, age or seasonality. The effect of sex was excluded 
with the inclusion of only male subjects; the possible effect of age on platelet 5-HT content was 
  
6
6
neglected as no significant relation between age and platelet 5-HT was found in healthy 
(Muck-Seler et al., 1996b; Pivac et al., 2001;  Pivac et al., 2004b) or PTSD (present study) 
subjects, and the possible seasonal influence on platelet 5-HT parameters (Jakovljevic et al., 
1997) was avoided since war veterans and healthy controls were sampled in the same season.  
The lack of significant relationship between platelet 5-HT and other subscales of 
PANSS or CAPS indicates that only delusions were associated with increased values of 
platelet 5-HT. In support to our data no association was found between platelet 5-HT and 
CAPS scores in less severely ill patients without psychotic symptoms (Pivac et al., 2002), or 
between platelet 5-HT content and uptake and scores measuring PTSD, depressive and 
anxiety symptoms (Maguire et al., 1998; Mellman and Kumar, 1994).  
Although psychotic PTSD is not recognized as a separate entity, 30-40% of combat 
related PTSD patients develop psychotic symptoms, which add to a more severe form of 
PTSD (Butler et al., 1996; Hamner, 1997; Hamner et al., 1999; Mueser et al., 2002; Kozaric-
Kovacic and Borovecki, 2005; Kozaric-Kovacic and Kocijan-Hercigonja, 2001; Kozaric-
Kovacic et al., 2005; Pivac et al., 2004a). Psychotic features in our PTSD patients were not 
due to previous comorbidity, as we excluded patients with previous Axis I disorders. 
Increased concentration of cerebrospinal fluid corticotrophin releasing hormone (Sautter et 
al., 2003), decreased activity of the plasma dopamine beta hydoxylase (Hamner and Gould, 
1998), and increased platelet 5-HT concentrations (present study) were found in psychotic 
PTSD, suggesting a biologically distinct psychotic PTSD subtype. 
  The limitation of the study was the use of peripheral marker, platelet 5-HT 
concentration. The advantage of the study was in the inclusion criteria of only drug-free war 
veterans with or without combat related PTSD, and/or psychotic symptoms, a large sample 
(N=138), and detailed clinical assessment with instrument measures such as SCID, CAPS and 
PANSS. 
 In conclusion, platelet 5-HT concentration was increased in war veterans with 
psychotic PTSD, and there was a significant relationship between psychotic symptoms, 
especially delusions, and platelet 5-HT concentration in these patients. The data suggest that 
platelet 5-HT concentration might be used as a trait marker for PTSD with psychotic features.  
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Figure 1: Platelet 5-HT concentration (mean ± SD) in war veterans with psychotic PTSD, war 
veterans with nonpsychotic PTSD, war veterans without PTSD, and in male healthy controls. 
Number of subjects is given in brackets. * p< 0.05 vs. platelet 5-HT concentration in war 
veterans with nonpsychotic PTSD, war veterans without PTSD or control subjects, Tukey’s 
test. 
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Table 1. Demographic data in war veterans with nonpsychotic or psychotic PTSD, and in war 
veterans without PTSD. Data are expressed as mean ± SD. Number of subjects is given in 
brackets. 
 
 
 
 
 
 
 War veterans (138) 
 With PTSD (102) 
 Nonpsychotic  (67) Psychotic (35) 
Without PTSD 
(36) 
Age (years) 40.7 ± 7.3 37.9 ± 8.0 37.7 ± 4.3 
PANSS total 73.3 ± 15.5 101.6 ± 16.4 36.0  ±  1.5 
PANSS positive 13.2 ± 3.8 23.3 ± 6.0 7.3  ± 0.5 
PANSS negative 10.5 ± 4.2 15.5 ± 4.8 7.4  ± 0.5 
PANSS gen. psychopathology 41.4 ± 8.1 52.6 ± 7.2 17.8 ± 0.8 
PANSS supplementary items 8.3 ± 2.4 10.7 ± 1.7 3.4 ± 0.5 
CAPS total 71.9 ± 4.3 98.3 ± 3.0 18.8 ± 11.5 
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Table 2. Pearson’s coefficient of correlation (r) between platelet 5-HT and scores in clinical 
scales (total and subscale scores in PANSS and in CAPS) and symptoms in PANSS positive 
subscale in war veterans with psychotic PTSD. 
Clinical scales correlation (r)            p 
CAPS total -0.061                            0.730 
PANSS total 0.068                         0.703 
PANSS positive 0.379                         0.027* 
PANSS negative -0.176                        0.319 
PANSS general psychopathology -0.056                        0.751 
PANSS supplementary items -0.007                        0.967 
  
Symptoms in PANSS positive subscale:  
-Delusion 0.448                          0.008* 
-Conceptual disorganization 0.303                          0.081 
-Hallucinatory behavior 0.312                          0.073 
-Excitement 0.076                          0.671 
-Grandiosity 0.115                          0.519 
-Suspicioness/persecution 0.180                          0.309 
-Hostility 0.161                          0.364 
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